

Freedom of Information Request: Our Reference CTHB_283_19

You asked:

- 1. Please complete the number of patients treated with Synagis (palivizumab) in the grid below. Please note that the total number of patients (A to E) in each column must add to total patients in the last row in the corresponding column.**

Please see our response provided in the table below.

Patients / babies treated with <u>Synagis</u> in the last three years (OPCS4: X865)	2016/17		2017/18	2018/19
A. Total number of patients with BPD / CLD diagnosis	0		0	**
B. Total number of patients with CHD diagnosis	0		0	0
C. Total number of <29wga (without BPD/CHD diagnosis)	0		0	0
D. Total number of multiple births immunised (without BPD/CHD diagnosis)	0		0	0
E. Other patients (please specify:	0		0	0
Total number of patients	0		0	**

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large.

The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

- 2. Please advise which OPCS codes are used within your Trust to code respiratory syncytial virus (RSV) prophylaxis treatment.**

This information is attached as Appendix 1 with the information regarding codes included on the cover sheet of the excel document.